文献速递骨软组织肉瘤与黑色素瘤

甲氨蝶呤、多柔比星和顺铂对比甲氨蝶呤、多柔比星和顺铂联合异环磷酰胺用于新诊断高级别骨肉瘤术前化疗反应不佳患者(JCOG0905):一项多中心、开放标签、随机试验

Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial.
PubMed 文献 · J Clin Oncol · 2025-03-26

JCOG0905多中心开放标签随机试验纳入新诊断高级别骨肉瘤患者,术前MAP两周期后肿瘤切除,反应不佳者随机接受MAP或MAP联合异环磷酰胺(MAPIF)。截至2022年3月,两组无病生存无差异(HR 1.05,95%CI 0.55-1.98),总生存MAPIF组数值上更差(HR 1.48,95%CI 0.68-3.22)。结论不支持对此类患者加用异环磷酰胺。

要点

  • 术前MAP化疗反应不佳的高级别骨肉瘤患者随机接受MAP或MAPIF。
  • 两组无病生存无差异,HR 1.05(95%CI 0.55-1.98)。
  • 总生存MAPIF组数值上更差,HR 1.48(95%CI 0.68-3.22)。

核心结论

  • JCOG0905的证据不支持对术前化疗反应不佳的高级别骨肉瘤患者加用异环磷酰胺。

研究设计与样本

  • 多中心、开放标签、随机试验,2010年2月至2020年8月共注册287例患者。
  • 符合条件的患者为50岁及以下、可切除的高级别骨肉瘤(UICC TNM分期II或III期),位于四肢、肢带和胸壁。
  • 接受两周期MAP化疗和肿瘤切除后,反应不佳者随机分配至MAP组或MAP联合异环磷酰胺(MAPIF)组。
  • MAPIF组异环磷酰胺剂量为15 g/m2(第1-5天每天一次3 g/m2)×六周期。
  • 主要终点为无病生存(DFS),次要终点为总生存(OS)和安全性;计划样本量100例,单侧α=0.1,把握度0.7,假设MAP组和MAPIF组3年DFS分别为50%和65%。

主要发现

  • 反应不佳患者中,51例分配至MAP组,52例分配至MAPIF组。
  • 截至2022年3月,两组DFS无差异(HR 1.05,95%CI 0.55-1.98)。
  • OS在MAPIF组数值上更差(HR 1.48,95%CI 0.68-3.22)。
  • 因不良事件中止治疗的患者在MAPIF组为9例,MAP组为0例。

临床怎么用

  • 原文结论为证据不支持对术前化疗反应不佳的高级别骨肉瘤患者加用异环磷酰胺。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m2 [4g/m2 once on day 1, then 2g/m2 once on days 2-7] × six) to patients showing a poor response (PrRsp) to preoperative chemotherapy with methotrexate, doxorubicin, and cisplatin (MAP) improves their prognoses. In this Japan Clinical Oncology Group (JCOG) study, JCOG0905, we aimed to investigate the efficacy and safety of IF in patients with PrRsp. METHODS: JCOG0905 is a multicenter, open-label, multi-institutional, randomized trial. Eligible patients (50 years and younger) had resectable, high-grade osteosarcoma (stage II or III, Union for International Cancer Control TNM) of the extremities, limb girdles, and thoracic wall. After two MAP cycles and tumor resection, patients with PrRsp were randomly assigned to either the MAP or MAP plus 15 g/m2 (3g/m2 once daily on days 1-5) × six IF (MAP + IF [MAPIF]) group. The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The planned sample size was 100 patients with a one-sided α of .1 and a power of 0.7, assuming a 3-year DFS of 50% and 65% for MAP and MAPIF, respectively. This trial is registered with the Japan Registry of Clinical Trials (jRCT; jRCTs031180126). RESULTS: Of the 287 patients registered between February 2010 and August 2020, 51 and 52 patients with PrRsp were assigned to the MAP and MAPIF groups, respectively. As of March 2022, DFS did not differ between groups (hazard ratio [HR], 1.05 [95% CI, 0.55 to 1.98]) and OS was numerically inferior in the MAPIF group (HR, 1.48 [95% CI, 0.68 to 3.22]). Nine and zero patients in the MAPIF and MAP groups discontinued treatment because of adverse events, respectively. CONCLUSION: Evidence from JCOG0905 does not support the addition of IF for patients with PrRsp.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hiraga H, Machida R, Kawai A, et al. Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial. J Clin Oncol. 2025. PMID: 40138604. doi:10.1200/JCO-24-01281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。